The emerging role of lactate in tumor microenvironment and its clinical relevance

Chen, Sihan; Xu, Yining; Zhuo, Wei; Zhang, Lu

doi:10.1016/j.canlet.2024.216837

Cited by 5 publications

(1 citation statement)

References 224 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TME is the cellular milieu in which neoplastic cells or cancer stem cells reside. These include the blood vessels surrounding tumor cells, immune cells, other nontumor cells, the extracellular matrix, and signaling molecules ( 17 , 18 ). The interactions between these components and tumor cells have a significant impact on tumor progression ( 19 , 20 ).…”

Section: Overview Of the Tmementioning

confidence: 99%

Recent advances in understanding the immune microenvironment in ovarian cancer

Chen,

Yang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The occurrence of ovarian cancer (OC) is a major factor in women’s mortality rates. Despite progress in medical treatments, like new drugs targeting homologous recombination deficiency, survival rates for OC patients are still not ideal. The tumor microenvironment (TME) includes cancer cells, fibroblasts linked to cancer (CAFs), immune-inflammatory cells, and the substances these cells secrete, along with non-cellular components in the extracellular matrix (ECM). First, the TME mainly plays a role in inhibiting tumor growth and protecting normal cell survival. As tumors progress, the TME gradually becomes a place to promote tumor cell progression. Immune cells in the TME have attracted much attention as targets for immunotherapy. Immune checkpoint inhibitor (ICI) therapy has the potential to regulate the TME, suppressing factors that facilitate tumor advancement, reactivating immune cells, managing tumor growth, and extending the survival of patients with advanced cancer. This review presents an outline of current studies on the distinct cellular elements within the OC TME, detailing their main functions and possible signaling pathways. Additionally, we examine immunotherapy rechallenge in OC, with a specific emphasis on the biological reasons behind resistance to ICIs.

show abstract